Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 139

1.

Epigenetic alterations in hematopoietic malignancies.

Chung YR, Schatoff E, Abdel-Wahab O.

Int J Hematol. 2012 Oct;96(4):413-27. doi: 10.1007/s12185-012-1181-z. Epub 2012 Sep 27. Review.

PMID:
23015417
[PubMed - indexed for MEDLINE]
2.

Somatic alterations and dysregulation of epigenetic modifiers in cancers.

Aumann S, Abdel-Wahab O.

Biochem Biophys Res Commun. 2014 Dec 5;455(1-2):24-34. doi: 10.1016/j.bbrc.2014.08.004. Epub 2014 Aug 9. Review.

PMID:
25111821
[PubMed - indexed for MEDLINE]
3.

TET2 as an epigenetic master regulator for normal and malignant hematopoiesis.

Nakajima H, Kunimoto H.

Cancer Sci. 2014 Sep;105(9):1093-9. doi: 10.1111/cas.12484. Epub 2014 Sep 3. Review.

PMID:
25040794
[PubMed - indexed for MEDLINE]
4.

TET genes: new players in DNA demethylation and important determinants for stemness.

Mohr F, Döhner K, Buske C, Rawat VP.

Exp Hematol. 2011 Mar;39(3):272-81. doi: 10.1016/j.exphem.2010.12.004. Epub 2010 Dec 17. Review.

PMID:
21168469
[PubMed - indexed for MEDLINE]
5.

Clinical implications of novel mutations in epigenetic modifiers in AML.

Abdel-Wahab O, Patel J, Levine RL.

Hematol Oncol Clin North Am. 2011 Dec;25(6):1119-33. doi: 10.1016/j.hoc.2011.09.013. Epub 2011 Oct 29. Review.

PMID:
22093580
[PubMed - indexed for MEDLINE]
6.

Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia.

Abdel-Wahab O, Levine RL.

Blood. 2013 May 2;121(18):3563-72. doi: 10.1182/blood-2013-01-451781. Review.

PMID:
23640996
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Role of epigenetic changes in hematological malignancies.

Lehmann U, Brakensiek K, Kreipe H.

Ann Hematol. 2004 Mar;83(3):137-52. Epub 2003 Dec 2. Review.

PMID:
15064862
[PubMed - indexed for MEDLINE]
8.

Disordered epigenetic regulation in the pathophysiology of myeloproliferative neoplasms.

Zhang SJ, Abdel-Wahab O.

Curr Hematol Malig Rep. 2012 Mar;7(1):34-42. doi: 10.1007/s11899-011-0105-y. Review.

PMID:
22170482
[PubMed - indexed for MEDLINE]
9.

Focus on the epigenome in the myeloproliferative neoplasms.

Kim E, Abdel-Wahab O.

Hematology Am Soc Hematol Educ Program. 2013;2013:538-44. doi: 10.1182/asheducation-2013.1.538. Review.

PMID:
24319229
[PubMed - indexed for MEDLINE]
Free Article
10.

Perturbations of 5-hydroxymethylcytosine patterning in hematologic malignancies.

Madzo J, Vasanthakumar A, Godley LA.

Semin Hematol. 2013 Jan;50(1):61-9. doi: 10.1053/j.seminhematol.2013.01.004. Review.

PMID:
23507484
[PubMed - indexed for MEDLINE]
11.

Mutational determinants of epigenetic instablity in myeloid malignancies.

Jankowska AM, Szpurka H.

Semin Oncol. 2012 Feb;39(1):80-96. doi: 10.1053/j.seminoncol.2011.11.006. Review.

PMID:
22289495
[PubMed - indexed for MEDLINE]
12.

Mutations in epigenetic regulators in myelodysplastic syndromes.

Nikoloski G, van der Reijden BA, Jansen JH.

Int J Hematol. 2012 Jan;95(1):8-16. doi: 10.1007/s12185-011-0996-3. Epub 2012 Jan 11. Review.

PMID:
22234528
[PubMed - indexed for MEDLINE]
13.

The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases.

Solary E, Bernard OA, Tefferi A, Fuks F, Vainchenker W.

Leukemia. 2014 Mar;28(3):485-96. doi: 10.1038/leu.2013.337. Epub 2013 Nov 13. Review.

PMID:
24220273
[PubMed - indexed for MEDLINE]
14.

Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies.

Li Z, Cai X, Cai CL, Wang J, Zhang W, Petersen BE, Yang FC, Xu M.

Blood. 2011 Oct 27;118(17):4509-18. doi: 10.1182/blood-2010-12-325241. Epub 2011 Jul 29.

PMID:
21803851
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

[An update on epigenetic regulator gene mutations and pathogenesis of myelodysplastic syndromes].

Wang JY, Xiao ZJ.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Oct;19(5):1303-9. Review. Chinese.

PMID:
22040993
[PubMed - indexed for MEDLINE]
16.

Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy.

Fathi AT, Abdel-Wahab O.

Adv Hematol. 2012;2012:469592. doi: 10.1155/2012/469592. Epub 2011 Jun 26.

PMID:
21811504
[PubMed]
Free PMC Article
17.

[Molecular mechanisms involved in epigenetic alterations in cancer].

Toyota M, Suzuki H, Nishizaka T, Sato A, Yamashita T.

Gan To Kagaku Ryoho. 2010 Sep;37(9):1650-3. Japanese.

PMID:
20841926
[PubMed - indexed for MEDLINE]
18.

Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.

Sigalotti L, Fratta E, Coral S, Cortini E, Covre A, Nicolay HJ, Anzalone L, Pezzani L, Di Giacomo AM, Fonsatti E, Colizzi F, Altomonte M, Calabrò L, Maio M.

J Cell Physiol. 2007 Aug;212(2):330-44. Review.

PMID:
17458893
[PubMed - indexed for MEDLINE]
19.

The role of mutations in epigenetic regulators in myeloid malignancies.

Shih AH, Abdel-Wahab O, Patel JP, Levine RL.

Nat Rev Cancer. 2012 Sep;12(9):599-612. doi: 10.1038/nrc3343. Epub 2012 Aug 17. Review.

PMID:
22898539
[PubMed - indexed for MEDLINE]
20.

TET2, ASXL1, IDH1, IDH2, and c-CBL genes in JAK2- and MPL-negative myeloproliferative neoplasms.

Martínez-Avilés L, Besses C, Álvarez-Larrán A, Torres E, Serrano S, Bellosillo B.

Ann Hematol. 2012 Apr;91(4):533-41. doi: 10.1007/s00277-011-1330-0. Epub 2011 Sep 9.

PMID:
21904853
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk